Home — Thanks to the outcomes of Nerviano Medical Sciences research on chordoma a Phase II study on the activity of an EGFR inhibitor was initiated

Thanks to the outcomes of Nerviano Medical Sciences research on chordoma a Phase II study on the activity of an EGFR inhibitor was initiated

Nerviano, Italy, 10.07.2018

Outcomes from Nerviano Medical Sciences research on chordoma, carried out in collaboration with the IRCCS Foundation of the National Cancer Institute of Milan, suggest a new therapeutical possible option for this rare and disabling tumor.

Three European research groups have, in fact, initiated a Phase II exploratory study to further evaluate the activity of afatinib, based on NMS recent data on chordoma biology and new evidences on activity this EGFR inhibitor.

Further information and an interview with Nerviano Medical Sciences researchers are available on the Rare Diseases Observatory